Who owns Aclaris Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ACRS from SEC Form 13F filings across 148 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 148 institutions disclosed 119.1M shares of Aclaris Therapeutics, Inc. worth $630.0M — about 83.5% of shares outstanding; the largest disclosed holder is RA CAPITAL MANAGEMENT, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
148
13F holders
$630.0M
value, 2026 filers
83.5%
of shares outstanding (119.1M sh)
27
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of ACRS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 12.7M | $67.3M | 0.6% | 8.9% | +87.0% |
| 2 | BML Capital Management, LLC | 12.0M | $63.3M | 36.0% | 8.4% | -16.0% |
| 3 | BlackRock, Inc. | 10.0M | $53.1M | 0.0% | 7% | +35.5% |
| 4 | Deep Track Capital, LP | 9.3M | $49.4M | 0.7% | 6.5% | 0.0% |
| 5 | Vivo Capital, LLC | 6.7M | $35.4M | 3.2% | 4.7% | +0.4% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 5.8M | $30.8M | 0.0% | 4.1% | +12.6% |
| 7 | Frazier Life Sciences Management, L.P. | 4.9M | $26.1M | 0.6% | 3.5% | 0.0% |
| 8 | Rock Springs Capital Management LP | 4.3M | $22.9M | 1.1% | 3% | -3.2% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.1M | $21.5M | 0.0% | 2.9% | +5.2% |
| 10 | Decheng Capital LLC | 4.0M | $21.4M | 2.9% | 2.8% | 0.0% |
| 11 | STATE STREET CORP | 3.3M | $17.2M | 0.0% | 2.3% | +62.1% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 3.2M | $16.9M | 0.0% | 2.2% | +31.6% |
| 13 | BRAIDWELL LP | 2.1M | $11.3M | 0.4% | 1.5% | +26.1% |
| 14 | Balyasny Asset Management L.P. | 2.0M | $10.7M | 0.0% | 1.4% | -39.8% |
| 15 | SILVERARC CAPITAL MANAGEMENT, LLCNEW | 1.9M | $10.3M | 1.1% | 1.4% | new |
| 16 | Kalehua Capital Management LLC | 1.8M | $9.7M | 6.9% | 1.3% | +37.0% |
| 17 | CITADEL ADVISORS LLC | 1.8M | $9.3M | 0.0% | 1.2% | -21.7% |
| 18 | Jones Hill Capital LPNEW | 1.8M | $9.3M | 2.0% | 1.2% | new |
| 19 | ACADIAN ASSET MANAGEMENT LLC | 1.6M | $8.7M | 0.0% | 1.1% | +6.6% |
| 20 | Palo Alto Investors LP | 1.6M | $8.5M | 1.2% | 1.1% | 0.0% |
| 21 | Woodline Partners LP | 1.6M | $8.5M | 0.0% | 1.1% | +8.4% |
| 22 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.5M | $7.8M | 0.0% | 1% | -11.5% |
| 23 | PANAGORA ASSET MANAGEMENT INC | 1.4M | $7.2M | 0.0% | 1% | +170.0% |
| 24 | Connor, Clark & Lunn Investment Management Ltd. | 1.2M | $6.4M | 0.0% | 0.8% | -14.7% |
| 25 | MPM BIOIMPACT LLC | 1.0M | $5.5M | 0.3% | 0.7% | +166.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.